Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK
S-E. Al-Batran(Krankenhaus Nordwest), Nils Homann(Fraunhofer Project Centre Wolfsburg), Eray Goekkurt(Sorbonne Université), Andreas Wicki(University Hospital of Basel), Jonathan Talbot(Roche (Switzerland)), Daniel Pink(Universitätsmedizin Greifswald), Ekkehard Eigendorff(Jena University Hospital), Claus Bolling(Agaplesion Markus Hospital), Ralf‐Dieter Hofheinz(University of Mannheim), Lisa Waberer(Krankenhaus Nordwest), Michael Geißler(Klinikum Esslingen), Harald Schmalenberg(Heidelberg University), Thorsten Oliver Goetze(Institute of Clinical Cancer Research), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Stefan Angermeier(Klinikum Ludwigsburg), Michael Schenk(Krankenhaus Barmherzige Brüder), Albrecht Kretzschmar(Roche (Switzerland)), Sylvie Lorenzen(Technical University of Munich), Alexander Siebenhuener(University Hospital Zurich), Claudia Pauligk(Goethe University Frankfurt)
Cited by 8
Related Papers
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k